



JUL 18 2005

JAN - 9 2006

Office of Regulatory Policy
HFD - 13
5600 Fishers Lane,
Rockville, MD 20857

Attention: Claudia Grillo


Dear Ms. Axelrad:

The attached application for patent term extension of U.S. Patent No. 5,424,286 was filed on June 24, 2005, under 35 U.S.C. § 156.

The assistance of your Office is requested in confirming that the product identified in the application, BYETTA™ (exenatide injection); has been subject to a regulatory review period within the meaning of 35 U.S.C. § 156(g) before its first commercial marketing or use and that the application for patent term extension was filed within the sixty-day period after the product was approved. Since a determination has not been made whether the patent in question claims a product which has been subject to the Federal Food, Drug and Cosmetic Act, or a method of manufacturing or use of such a product, this communication is NOT to be considered as notice which may be made in the future pursuant to 35 U.S.C. § 156(d)(2)(A).

Our review of the application to date indicates that the subject patent would be eligible for extension of the patent term under 35 U.S.C. § 156.

Inquiries regarding this communication should be directed to Mary C. Till at (571) 272-7755 (telephone) or (571)273-7755 (facsimile).


Karin Ferriter
Senior Legal Advisor
Office of Patent Legal Administration
Office of the Deputy Commissioner
for Patent Examination Policy

cc: Molly A. Holman, Ph.D., J.D.
Executive Director, Intellectual Property
Amylin Pharmaceuticals, Inc.
9360 Towne Centre Drive
San Diego, CA 92121